logo
  • Home
  • Company
    • Back
    • About Us
      • Back
    • Leadership
      • Back
      • Corporate Executive Team
        • Back
      • Board Of Directors
        • Back
      • Strategic Advisors
        • Back
  • Science
    • Back
    • Our Focus
    • Pipeline
      • Back
      • Infectious Disease Programs
        • Back
      • Central Nervous System Disease Programs
        • Back
    • Literature Archive
      • Back
  • Media
    • Back
    • Press Release
      • Back
      • Brii Biosciences Announces Upcoming Conference Participation in November
      • Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
      • Brii Biosciences to Present New Phase 1 Data from HIV Program at IDWeek 2022
      • Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression
      • Brii Biosciences Announces China Leadership Team Changes
      • Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum
      • Brii Biosciences Announces Upcoming Conference Participation in September
      • Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results
      • WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics
      • Brii Biosciences Builds Innovative Pipeline, Forges Public-Private Partnerships to Bring Novel Medicines to Chinese Patients
      • FierceBiotech names Brii Biosciences as one of its “Fierce 15” Biotech Companies of 2018
      • Brii Biosciences Launches to Bring Innovative Medicines to Chinese Patients
      • VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection
      • Brii Biosciences Expands Infectious Disease Pipeline
      • Brii Biosciences Expands Therapeutic Focus to Include Neurosciences with Addition of John Kraus, M.D., Ph.D.
      • Brii Biosciences Provides Corporate Update on Progress Against Strategic R&D Priorities
      • Brii Biosciences Appoints Rogers Luo, Ankang Li To Leadership Positions
      • Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19
      • Brii Biosciences Provides Funding to Columbia University for Research on COVID-19 and Other Coronaviruses
      • Brii Biosciences Antibody Combination Will Not Progress into a Phase 3 Study Evaluating the Treatment of SARS-CoV-2 in Hospitalized Patients
      • Brii Biosciences Closes US$155 Million Series C Financing
      • Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
      • Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients
      • Brii Biosciences Provides Update on Strategic Clinical Development Progress
      • Brii Biosciences to Present Updated Phase 1b/2a Data on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
      • Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
      • Brii Biosciences Limited Successfully Listed on Main Board of Hong Kong Stock Exchange
      • Brii Biosciences Initiates Phase 2 Clinical Trial in China for Neutralizing Antibodies, BRII-196 and BRII-198, in SARS-CoV-2
      • Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19
      • Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
      • Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients
      • Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy
      • Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease
      • Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company’s SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021
      • Brii Biosciences Announces Upcoming Participation at November Conferences
      • Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit
      • Brii Biosciences Joins Hang Seng Composite Index
      • Brii Biosciences Included in Hong Kong Stock Connect
      • Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China
      • Brii Biosciences Receives Clinical Hold Notification from US. FDA on BRII-732
      • Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant
      • Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B
      • Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head
      • Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants
      • Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
      • Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer
      • Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China
      • Brii Biosciences Exercises Option for Vir Biotechnology’s VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China
      • Brii Biosciences Announces Upcoming Conference Participation in July
      • Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
      • Brii Bio Announces GMP Compliance Inspection Result for the Amubarvimab Injection and Romlusevimab Injection
      • Brii Biosciences Announces Upcoming Conference Participation in June
      • Brii Biosciences to be Added to MSCI China Small Cap Index
      • Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
      • Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report
      • Brii Biosciences Announces Upcoming Participation at May Conference
      • Brii Biosciences Announces Upcoming Participation at April Conferences
      • Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
      • Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
      • Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results
      • Brii Bio to Present Phase 2 Data on Two Monthly Doses of BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
      • Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition)
      • Brii Biosciences Announces Upcoming Participation at March Conferences
      • Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources
      • Brii Biosciences Announces Upcoming Conference Participation in January
      • Brii Biosciences Provides Update on Strategic Clinical Development Progress
    • Media Reports
      • Back
  • Investor Relations
    • Back
    • Fact Sheet
    • Corporate Governance
      • Back
      • Board of Directors
        • Back
      • Committee Composition
        • Back
      • Corporate Governance Documents
        • Back
    • Listing Documents
      • Back
    • Announcements & Circulars
    • Share Graph
    • Financial Calendar
    • Presentation & Webcast
      • Back
      • Webcasts
        • Back
      • Presentations
        • Back
    • Financial Reports
    • IR Enquiries & Email Alert
    • Analyst Coverage
    • Replacement of Lost Share Certificates
      • Back
  • Careers
  • Contact Us
Linkedin Wechat
qr
EN 简 繁
EN 简 繁
  • Home
  • Company
    • Back
    • About Us
      • Back
    • Leadership
      • Back
      • Corporate Executive Team
        • Back
      • Board Of Directors
        • Back
      • Strategic Advisors
        • Back
  • Science
    • Back
    • Our Focus
    • Pipeline
      • Back
      • Infectious Disease Programs
        • Back
      • Central Nervous System Disease Programs
        • Back
    • Literature Archive
      • Back
  • Media
    • Back
    • Press Release
      • Back
      • Brii Biosciences Announces Upcoming Conference Participation in November
      • Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
      • Brii Biosciences to Present New Phase 1 Data from HIV Program at IDWeek 2022
      • Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression
      • Brii Biosciences Announces China Leadership Team Changes
      • Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum
      • Brii Biosciences Announces Upcoming Conference Participation in September
      • Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results
      • WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics
      • Brii Biosciences Builds Innovative Pipeline, Forges Public-Private Partnerships to Bring Novel Medicines to Chinese Patients
      • FierceBiotech names Brii Biosciences as one of its “Fierce 15” Biotech Companies of 2018
      • Brii Biosciences Launches to Bring Innovative Medicines to Chinese Patients
      • VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection
      • Brii Biosciences Expands Infectious Disease Pipeline
      • Brii Biosciences Expands Therapeutic Focus to Include Neurosciences with Addition of John Kraus, M.D., Ph.D.
      • Brii Biosciences Provides Corporate Update on Progress Against Strategic R&D Priorities
      • Brii Biosciences Appoints Rogers Luo, Ankang Li To Leadership Positions
      • Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19
      • Brii Biosciences Provides Funding to Columbia University for Research on COVID-19 and Other Coronaviruses
      • Brii Biosciences Antibody Combination Will Not Progress into a Phase 3 Study Evaluating the Treatment of SARS-CoV-2 in Hospitalized Patients
      • Brii Biosciences Closes US$155 Million Series C Financing
      • Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
      • Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients
      • Brii Biosciences Provides Update on Strategic Clinical Development Progress
      • Brii Biosciences to Present Updated Phase 1b/2a Data on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
      • Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
      • Brii Biosciences Limited Successfully Listed on Main Board of Hong Kong Stock Exchange
      • Brii Biosciences Initiates Phase 2 Clinical Trial in China for Neutralizing Antibodies, BRII-196 and BRII-198, in SARS-CoV-2
      • Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19
      • Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
      • Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients
      • Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy
      • Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease
      • Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company’s SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021
      • Brii Biosciences Announces Upcoming Participation at November Conferences
      • Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit
      • Brii Biosciences Joins Hang Seng Composite Index
      • Brii Biosciences Included in Hong Kong Stock Connect
      • Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China
      • Brii Biosciences Receives Clinical Hold Notification from US. FDA on BRII-732
      • Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant
      • Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B
      • Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head
      • Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants
      • Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
      • Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer
      • Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China
      • Brii Biosciences Exercises Option for Vir Biotechnology’s VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China
      • Brii Biosciences Announces Upcoming Conference Participation in July
      • Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
      • Brii Bio Announces GMP Compliance Inspection Result for the Amubarvimab Injection and Romlusevimab Injection
      • Brii Biosciences Announces Upcoming Conference Participation in June
      • Brii Biosciences to be Added to MSCI China Small Cap Index
      • Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
      • Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report
      • Brii Biosciences Announces Upcoming Participation at May Conference
      • Brii Biosciences Announces Upcoming Participation at April Conferences
      • Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
      • Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
      • Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results
      • Brii Bio to Present Phase 2 Data on Two Monthly Doses of BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
      • Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition)
      • Brii Biosciences Announces Upcoming Participation at March Conferences
      • Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources
      • Brii Biosciences Announces Upcoming Conference Participation in January
      • Brii Biosciences Provides Update on Strategic Clinical Development Progress
    • Media Reports
      • Back
  • Investor Relations
    • Back
    • Fact Sheet
    • Corporate Governance
      • Back
      • Board of Directors
        • Back
      • Committee Composition
        • Back
      • Corporate Governance Documents
        • Back
    • Listing Documents
      • Back
    • Announcements & Circulars
    • Share Graph
    • Financial Calendar
    • Presentation & Webcast
      • Back
      • Webcasts
        • Back
      • Presentations
        • Back
    • Financial Reports
    • IR Enquiries & Email Alert
    • Analyst Coverage
    • Replacement of Lost Share Certificates
      • Back
  • Careers
  • Contact Us

Presentation & Webcast

Presentation & Webcast

  • Webcasts
  • Presentations
Aug 24, 2022
Brii Biosciences 2022 Interim Results Conference Call
Brii Biosciences 2022 Interim Results Conference Call
Jul 08, 2022
Brii Biosciences COVID-19 Neutralizing Amubarvimab/Romlusevimab Commercial Launch
Brii Biosciences COVID-19 Neutralizing Amubarvimab/Romlusevimab Commercial Launch
Jun 27, 2022
Brii Bio at H.C. Wainwright 1st Annual Mental Health Conference
Brii Bio at H.C. Wainwright 1st Annual Mental Health Conference
Mar 23, 2022
Brii Biosciences Full Year 2021 Financial Results and Corporate Progress Update Conference Call
Brii Biosciences Full Year 2021 Financial Results and Corporate Progress Update Conference Call
Dec 13, 2021
Business Update Call: HIV Ph 1 Study Status
Business Update Call: HIV Ph 1 Study Status
Dec 12, 2021
Business Update Call: Combination Antibody Retains Neutralizing Activity Against Omicron Variant
Business Update Call: Combination Antibody Retains Neutralizing Activity Against Omicron Variant
Aug 27, 2021
Brii Biosciences 2021 Interim Results Conference Call
Brii Biosciences 2021 Interim Results Conference Call
Jan 11, 2023
Corporate Presentation
Corporate Presentation
Jun 27, 2022
HCW Mental Health Conference Presentation
HCW Mental Health Conference Presentation
logo
Linkedin Wechat
qr
info@BriiBio.com
icon
  • Home
  • Company
    • Back
    • About Us
      • Back
    • Leadership
      • Back
      • Corporate Executive Team
        • Back
      • Board Of Directors
        • Back
      • Strategic Advisors
        • Back
  • Science
    • Back
    • Our Focus
    • Pipeline
      • Back
      • Infectious Disease Programs
        • Back
      • Central Nervous System Disease Programs
        • Back
    • Literature Archive
      • Back
  • Media
    • Back
    • Press Release
      • Back
      • Brii Biosciences Announces Upcoming Conference Participation in November
      • Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
      • Brii Biosciences to Present New Phase 1 Data from HIV Program at IDWeek 2022
      • Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression
      • Brii Biosciences Announces China Leadership Team Changes
      • Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum
      • Brii Biosciences Announces Upcoming Conference Participation in September
      • Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results
      • WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics
      • Brii Biosciences Builds Innovative Pipeline, Forges Public-Private Partnerships to Bring Novel Medicines to Chinese Patients
      • FierceBiotech names Brii Biosciences as one of its “Fierce 15” Biotech Companies of 2018
      • Brii Biosciences Launches to Bring Innovative Medicines to Chinese Patients
      • VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection
      • Brii Biosciences Expands Infectious Disease Pipeline
      • Brii Biosciences Expands Therapeutic Focus to Include Neurosciences with Addition of John Kraus, M.D., Ph.D.
      • Brii Biosciences Provides Corporate Update on Progress Against Strategic R&D Priorities
      • Brii Biosciences Appoints Rogers Luo, Ankang Li To Leadership Positions
      • Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19
      • Brii Biosciences Provides Funding to Columbia University for Research on COVID-19 and Other Coronaviruses
      • Brii Biosciences Antibody Combination Will Not Progress into a Phase 3 Study Evaluating the Treatment of SARS-CoV-2 in Hospitalized Patients
      • Brii Biosciences Closes US$155 Million Series C Financing
      • Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
      • Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients
      • Brii Biosciences Provides Update on Strategic Clinical Development Progress
      • Brii Biosciences to Present Updated Phase 1b/2a Data on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
      • Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
      • Brii Biosciences Limited Successfully Listed on Main Board of Hong Kong Stock Exchange
      • Brii Biosciences Initiates Phase 2 Clinical Trial in China for Neutralizing Antibodies, BRII-196 and BRII-198, in SARS-CoV-2
      • Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19
      • Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
      • Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients
      • Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy
      • Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease
      • Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company’s SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021
      • Brii Biosciences Announces Upcoming Participation at November Conferences
      • Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit
      • Brii Biosciences Joins Hang Seng Composite Index
      • Brii Biosciences Included in Hong Kong Stock Connect
      • Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China
      • Brii Biosciences Receives Clinical Hold Notification from US. FDA on BRII-732
      • Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant
      • Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B
      • Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head
      • Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants
      • Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
      • Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer
      • Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China
      • Brii Biosciences Exercises Option for Vir Biotechnology’s VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China
      • Brii Biosciences Announces Upcoming Conference Participation in July
      • Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
      • Brii Bio Announces GMP Compliance Inspection Result for the Amubarvimab Injection and Romlusevimab Injection
      • Brii Biosciences Announces Upcoming Conference Participation in June
      • Brii Biosciences to be Added to MSCI China Small Cap Index
      • Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
      • Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report
      • Brii Biosciences Announces Upcoming Participation at May Conference
      • Brii Biosciences Announces Upcoming Participation at April Conferences
      • Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
      • Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
      • Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results
      • Brii Bio to Present Phase 2 Data on Two Monthly Doses of BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
      • Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition)
      • Brii Biosciences Announces Upcoming Participation at March Conferences
      • Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources
      • Brii Biosciences Announces Upcoming Conference Participation in January
      • Brii Biosciences Provides Update on Strategic Clinical Development Progress
    • Media Reports
      • Back
  • Investor Relations
    • Back
    • Fact Sheet
    • Corporate Governance
      • Back
      • Board of Directors
        • Back
      • Committee Composition
        • Back
      • Corporate Governance Documents
        • Back
    • Listing Documents
      • Back
    • Announcements & Circulars
    • Share Graph
    • Financial Calendar
    • Presentation & Webcast
      • Back
      • Webcasts
        • Back
      • Presentations
        • Back
    • Financial Reports
    • IR Enquiries & Email Alert
    • Analyst Coverage
    • Replacement of Lost Share Certificates
      • Back
  • Careers
  • Contact Us

© 2022 Brii Biosciences. All Rights Reserved.

| Developed by Euroland IR
Privacy Statement Terms of Use

This website uses cookies and similar technologies, to enhance your browsing experience and provide personalized recommendations. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy